Akorn, Inc. has successfully completed a re-inspection by the U.S. FDA conducted of its Decatur, IL manufacturing facility from December 5-9, with no Form 483 observations.     The re-inspection was conducted to verify the implementation and effectiveness of Akorn’s responses to the observations from the June 2016 FDA inspection.   Akorn is a specialty generic pharma company that develops, manufactures and markets multisource and branded pharmaceuticals. Akorn also has manufacturing faciliti...